{"id":"https://openalex.org/W2000246970","doi":"https://doi.org/10.4161/mabs.26201","title":"CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery","display_name":"CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery","publication_year":2013,"publication_date":"2013-08-21","ids":{"openalex":"https://openalex.org/W2000246970","doi":"https://doi.org/10.4161/mabs.26201","mag":"2000246970","pmid":"https://pubmed.ncbi.nlm.nih.gov/23995618","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3896602"},"language":"en","primary_location":{"id":"doi:10.4161/mabs.26201","doi":"https://doi.org/10.4161/mabs.26201","is_oa":true,"landing_page_url":"https://doi.org/10.4161/mabs.26201","pdf_url":"https://www.tandfonline.com/doi/pdf/10.4161/mabs.26201?needAccess=true","source":{"id":"https://openalex.org/S169123381","display_name":"mAbs","issn_l":"1942-0862","issn":["1942-0862","1942-0870"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315740","host_organization_name":"Landes Bioscience","host_organization_lineage":["https://openalex.org/P4310315740"],"host_organization_lineage_names":["Landes Bioscience"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2000246970"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.tandfonline.com/doi/pdf/10.4161/mabs.26201?needAccess=true","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111621562","display_name":"Brian J. Fennell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210166375","display_name":"Pfizer (Ireland)","ror":"https://ror.org/05y381977","country_code":"IE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210166375"]}],"countries":["IE","US"],"is_corresponding":false,"raw_author_name":"Brian J Fennell","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","Dublin, Ireland","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","institution_ids":["https://openalex.org/I4210166375"]},{"raw_affiliation_string":"Dublin, Ireland","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Barry McDonnell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210166375","display_name":"Pfizer (Ireland)","ror":"https://ror.org/05y381977","country_code":"IE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210166375"]}],"countries":["IE","US"],"is_corresponding":false,"raw_author_name":"Barry McDonnell","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","Dublin, Ireland","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","institution_ids":["https://openalex.org/I4210166375"]},{"raw_affiliation_string":"Dublin, Ireland","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102862229","display_name":"Amy Sze Pui Tam","orcid":"https://orcid.org/0009-0004-0832-5093","observed_orcids":["https://orcid.org/0009-0004-0832-5093"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy Sze Pui Tam","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085191179","display_name":"Lijun Chang","orcid":"https://orcid.org/0000-0002-6348-6496","observed_orcids":["https://orcid.org/0000-0002-6348-6496","https://orcid.org/0009-0006-5962-627X"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lijun Chang","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies, Foresterhill; Aberdeen, UK","Aberdeen, UK","Global Biotherapeutics Technologies, Foresterhill","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies, Foresterhill; Aberdeen, UK","institution_ids":[]},{"raw_affiliation_string":"Aberdeen, UK","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies, Foresterhill","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109911043","display_name":"John Steven","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Steven","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies, Foresterhill; Aberdeen, UK","Aberdeen, UK","Global Biotherapeutics Technologies, Foresterhill","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies, Foresterhill; Aberdeen, UK","institution_ids":[]},{"raw_affiliation_string":"Aberdeen, UK","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies, Foresterhill","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028020059","display_name":"Ian D. Broadbent","orcid":"https://orcid.org/0000-0002-2671-5480","observed_orcids":["https://orcid.org/0000-0002-2671-5480"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian D Broadbent","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies, Foresterhill; Aberdeen, UK","Aberdeen, UK","Global Biotherapeutics Technologies, Foresterhill","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies, Foresterhill; Aberdeen, UK","institution_ids":[]},{"raw_affiliation_string":"Aberdeen, UK","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies, Foresterhill","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039599059","display_name":"Huilan Gao","orcid":"https://orcid.org/0009-0001-8587-2419","observed_orcids":["https://orcid.org/0009-0001-8587-2419"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Huilan Gao","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083659157","display_name":"Elizabeth Kieras","orcid":"https://orcid.org/0000-0001-6920-1079","observed_orcids":["https://orcid.org/0000-0001-6920-1079"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Kieras","raw_affiliation_strings":["Pfizer; Immunoscience; Cambridge, MA USA","Cambridge, MA USA","Immunoscience","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Immunoscience; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Immunoscience","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011581117","display_name":"Jennifer Alley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Alley","raw_affiliation_strings":["Pfizer; Immunoscience; Cambridge, MA USA","Cambridge, MA USA","Immunoscience","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Immunoscience; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Immunoscience","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045641515","display_name":"Deborah P. Luxenberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah Luxenberg","raw_affiliation_strings":["Pfizer; Immunoscience; Cambridge, MA USA","Cambridge, MA USA","Immunoscience","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Immunoscience; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Immunoscience","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054318695","display_name":"Jason Edmonds","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Edmonds","raw_affiliation_strings":["Pfizer; Immunoscience; Cambridge, MA USA","Cambridge, MA USA","Immunoscience","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Immunoscience; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Immunoscience","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009869240","display_name":"Lori J. Fitz","orcid":"https://orcid.org/0000-0001-7989-5211","observed_orcids":["https://orcid.org/0000-0001-7989-5211"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lori J Fitz","raw_affiliation_strings":["Pfizer; Immunoscience; Cambridge, MA USA","Cambridge, MA USA","Immunoscience","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Immunoscience; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Immunoscience","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111640613","display_name":"Wenyan Miao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wenyan Miao","raw_affiliation_strings":["Pfizer; Immunoscience; Cambridge, MA USA","Cambridge, MA USA","Immunoscience","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Immunoscience; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Immunoscience","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111403294","display_name":"Matthew J. Whitters","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew J Whitters","raw_affiliation_strings":["Pfizer; Immunoscience; Cambridge, MA USA","Cambridge, MA USA","Immunoscience","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Immunoscience; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Immunoscience","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064407039","display_name":"Quintus G. Medley","orcid":"https://orcid.org/0000-0002-4646-3532","observed_orcids":["https://orcid.org/0000-0002-4646-3532"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Quintus G Medley","raw_affiliation_strings":["Pfizer; Immunoscience; Cambridge, MA USA","Cambridge, MA USA","Immunoscience","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Immunoscience; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Immunoscience","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102430322","display_name":"Yongjing Guo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yongjing J Guo","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030861371","display_name":"Alfredo Darmanin-Sheehan","orcid":"https://orcid.org/0000-0001-5280-7090","observed_orcids":["https://orcid.org/0000-0001-5280-7090"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210166375","display_name":"Pfizer (Ireland)","ror":"https://ror.org/05y381977","country_code":"IE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210166375"]}],"countries":["IE","US"],"is_corresponding":false,"raw_author_name":"Alfredo Darmanin-Sheehan","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","Dublin, Ireland","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","institution_ids":["https://openalex.org/I4210166375"]},{"raw_affiliation_string":"Dublin, Ireland","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013038056","display_name":"B\u00e9n\u00e9dicte Autin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210166375","display_name":"Pfizer (Ireland)","ror":"https://ror.org/05y381977","country_code":"IE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210166375"]}],"countries":["IE","US"],"is_corresponding":false,"raw_author_name":"B\u00e9n\u00e9dicte Autin","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","Dublin, Ireland","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","institution_ids":["https://openalex.org/I4210166375"]},{"raw_affiliation_string":"Dublin, Ireland","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008918416","display_name":"Deirdre N\u00ed Sh\u00failleabh\u00e1in","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210166375","display_name":"Pfizer (Ireland)","ror":"https://ror.org/05y381977","country_code":"IE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210166375"]}],"countries":["IE","US"],"is_corresponding":false,"raw_author_name":"Deirdre N\u00ed Sh\u00failleabh\u00e1in","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","Dublin, Ireland","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","institution_ids":["https://openalex.org/I4210166375"]},{"raw_affiliation_string":"Dublin, Ireland","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103105977","display_name":"Emma Cummins","orcid":"https://orcid.org/0000-0002-5193-7261","observed_orcids":["https://orcid.org/0000-0002-5193-7261"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210166375","display_name":"Pfizer (Ireland)","ror":"https://ror.org/05y381977","country_code":"IE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210166375"]}],"countries":["IE","US"],"is_corresponding":false,"raw_author_name":"Emma Cummins","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","Dublin, Ireland","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","institution_ids":["https://openalex.org/I4210166375"]},{"raw_affiliation_string":"Dublin, Ireland","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033374968","display_name":"Amy C. King","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy King","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019692071","display_name":"Mark R.H. Krebs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark RH Krebs","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Christopher Grace","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Christopher Grace","raw_affiliation_strings":["Pfizer; Pharmacokinetics, Dynamics, and Metabolism; Sandwich, UK","Pfizer","Pharmacokinetics, Dynamics, and Metabolism","Sandwich, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Pharmacokinetics, Dynamics, and Metabolism; Sandwich, UK","institution_ids":["https://openalex.org/I189718659"]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pharmacokinetics, Dynamics, and Metabolism","institution_ids":[]},{"raw_affiliation_string":"Sandwich, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081850567","display_name":"Timothy Paul Hickling","orcid":"https://orcid.org/0000-0002-8918-2140","observed_orcids":["https://orcid.org/0000-0002-8918-2140"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Timothy P Hickling","raw_affiliation_strings":["Pfizer; Pharmacokinetics, Dynamics, and Metabolism; Sandwich, UK","Pfizer","Pharmacokinetics, Dynamics, and Metabolism","Sandwich, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Pharmacokinetics, Dynamics, and Metabolism; Sandwich, UK","institution_ids":["https://openalex.org/I189718659"]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pharmacokinetics, Dynamics, and Metabolism","institution_ids":[]},{"raw_affiliation_string":"Sandwich, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019761881","display_name":"Angela Boisvert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Angela Boisvert","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065159436","display_name":"Xiaotian Zhong","orcid":"https://orcid.org/0000-0002-7505-6485","observed_orcids":["https://orcid.org/0000-0002-7505-6485"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaotian Zhong","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Matthew McKenna","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew McKenna","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068366112","display_name":"Christopher Francis","orcid":"https://orcid.org/0000-0002-9809-2286","observed_orcids":["https://orcid.org/0000-0002-9809-2286"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Francis","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002116098","display_name":"St\u00e9phane Olland","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephane Olland","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087718364","display_name":"Laird Bloom","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laird Bloom","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016629707","display_name":"Janet E. Paulsen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Janet Paulsen","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077358980","display_name":"Will Somers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Will Somers","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003216139","display_name":"Allan D. Jensen","orcid":"https://orcid.org/0000-0003-1103-2860","observed_orcids":["https://orcid.org/0000-0003-1103-2860"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Allan Jensen","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062835519","display_name":"Laura Lin","orcid":"https://orcid.org/0000-0003-1619-7437","observed_orcids":["https://orcid.org/0000-0003-1619-7437"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Lin","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","Cambridge, MA USA","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Cambridge, MA USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Cambridge, MA USA","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113831662","display_name":"William J.J. Finlay","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210166375","display_name":"Pfizer (Ireland)","ror":"https://ror.org/05y381977","country_code":"IE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210166375"]}],"countries":["IE","US"],"is_corresponding":false,"raw_author_name":"William JJ Finlay","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","Dublin, Ireland","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","institution_ids":["https://openalex.org/I4210166375"]},{"raw_affiliation_string":"Dublin, Ireland","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015817005","display_name":"Orla Cunningham","orcid":"https://orcid.org/0000-0002-3888-9541","observed_orcids":["https://orcid.org/0000-0002-3888-9541"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]},{"id":"https://openalex.org/I4210166375","display_name":"Pfizer (Ireland)","ror":"https://ror.org/05y381977","country_code":"IE","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210166375"]}],"countries":["IE","US"],"is_corresponding":true,"raw_author_name":"Orla Cunningham","raw_affiliation_strings":["Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","Dublin, Ireland","Global Biotherapeutics Technologies","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer; Global Biotherapeutics Technologies; Dublin, Ireland","institution_ids":["https://openalex.org/I4210166375"]},{"raw_affiliation_string":"Dublin, Ireland","institution_ids":[]},{"raw_affiliation_string":"Global Biotherapeutics Technologies","institution_ids":[]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5015817005"],"corresponding_institution_ids":["https://openalex.org/I180857899","https://openalex.org/I4210166375"],"apc_list":{"value":2915,"currency":"GBP","value_usd":3575},"apc_paid":{"value":2915,"currency":"GBP","value_usd":3575},"fwci":1.3078,"has_fulltext":false,"cited_by_count":33,"citation_normalized_percentile":{"value":0.77042975,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"5","issue":"6","first_page":"882","last_page":"895"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11124","display_name":"Protein purification and stability","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13326","display_name":"Biochemical and Structural Characterization","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cxcl13","display_name":"CXCL13","score":0.9160000085830688},{"id":"https://openalex.org/keywords/hypervariable-region","display_name":"hypervariable region","score":0.7279999852180481},{"id":"https://openalex.org/keywords/thermal-stability","display_name":"thermal stability","score":0.703000009059906},{"id":"https://openalex.org/keywords/affinity-maturation","display_name":"affinity maturation","score":0.6439999938011169},{"id":"https://openalex.org/keywords/phage-display","display_name":"phage display","score":0.6830000281333923},{"id":"https://openalex.org/keywords/subcutaneous-delivery","display_name":"subcutaneous delivery","score":0.8149999976158142},{"id":"https://openalex.org/keywords/high-concentration-formulations","display_name":"high-concentration formulations","score":0.6859999895095825},{"id":"https://openalex.org/keywords/inflammatory-mediators","display_name":"inflammatory mediators","score":0.6690000295639038},{"id":"https://openalex.org/keywords/immunomodulation","display_name":"immunomodulation","score":0.5680000185966492}],"concepts":[{"id":"https://openalex.org/C2781377902","wikidata":"https://www.wikidata.org/wiki/Q21418769","display_name":"Affinity maturation","level":3,"score":0.6796375513076782},{"id":"https://openalex.org/C186268636","wikidata":"https://www.wikidata.org/wiki/Q896217","display_name":"Phage display","level":3,"score":0.5899742841720581},{"id":"https://openalex.org/C85630698","wikidata":"https://www.wikidata.org/wiki/Q3826179","display_name":"Complementarity determining region","level":4,"score":0.5884949564933777},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5721546411514282},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.5442559719085693},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5066545605659485},{"id":"https://openalex.org/C2780557392","wikidata":"https://www.wikidata.org/wiki/Q523796","display_name":"Linker","level":2,"score":0.5011763572692871},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.47572019696235657},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.46615609526634216},{"id":"https://openalex.org/C147816474","wikidata":"https://www.wikidata.org/wiki/Q169525","display_name":"Protein engineering","level":3,"score":0.4454793632030487},{"id":"https://openalex.org/C125823703","wikidata":"https://www.wikidata.org/wiki/Q1616930","display_name":"Fragment crystallizable region","level":3,"score":0.430825412273407},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.42649444937705994},{"id":"https://openalex.org/C2776471321","wikidata":"https://www.wikidata.org/wiki/Q7166526","display_name":"Peptide library","level":4,"score":0.41533833742141724},{"id":"https://openalex.org/C2780443040","wikidata":"https://www.wikidata.org/wiki/Q3737863","display_name":"Bifunctional","level":3,"score":0.41436415910720825},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.27333396673202515},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.252599835395813},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.24149635434150696},{"id":"https://openalex.org/C2779281246","wikidata":"https://www.wikidata.org/wiki/Q172847","display_name":"Peptide","level":2,"score":0.17465302348136902},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.15630385279655457},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.14895367622375488},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.14159730076789856},{"id":"https://openalex.org/C167625842","wikidata":"https://www.wikidata.org/wiki/Q899763","display_name":"Peptide sequence","level":3,"score":0.12447980046272278},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.09847915172576904},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0},{"id":"https://openalex.org/C161790260","wikidata":"https://www.wikidata.org/wiki/Q82264","display_name":"Catalysis","level":2,"score":0.0},{"id":"https://openalex.org/C111919701","wikidata":"https://www.wikidata.org/wiki/Q9135","display_name":"Operating system","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001435","descriptor_name":"Bacteriophages","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D004797","descriptor_name":"Enzyme-Linked Immunosorbent Assay","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013696","descriptor_name":"Temperature","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015202","descriptor_name":"Protein Engineering","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D019151","descriptor_name":"Peptide Library","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D022801","descriptor_name":"Complementarity Determining Regions","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055550","descriptor_name":"Protein Stability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057127","descriptor_name":"Single-Chain Antibodies","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D057127","descriptor_name":"Single-Chain Antibodies","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D057127","descriptor_name":"Single-Chain Antibodies","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.4161/mabs.26201","doi":"https://doi.org/10.4161/mabs.26201","is_oa":true,"landing_page_url":"https://doi.org/10.4161/mabs.26201","pdf_url":"https://www.tandfonline.com/doi/pdf/10.4161/mabs.26201?needAccess=true","source":{"id":"https://openalex.org/S169123381","display_name":"mAbs","issn_l":"1942-0862","issn":["1942-0862","1942-0870"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315740","host_organization_name":"Landes Bioscience","host_organization_lineage":["https://openalex.org/P4310315740"],"host_organization_lineage_names":["Landes Bioscience"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2889142","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/articles/PMC3896602","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmid:23995618","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23995618","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:3896602","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3896602/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"MAbs","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.4161/mabs.26201","doi":"https://doi.org/10.4161/mabs.26201","is_oa":true,"landing_page_url":"https://doi.org/10.4161/mabs.26201","pdf_url":"https://www.tandfonline.com/doi/pdf/10.4161/mabs.26201?needAccess=true","source":{"id":"https://openalex.org/S169123381","display_name":"mAbs","issn_l":"1942-0862","issn":["1942-0862","1942-0870"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315740","host_organization_name":"Landes Bioscience","host_organization_lineage":["https://openalex.org/P4310315740"],"host_organization_lineage_names":["Landes Bioscience"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"mAbs","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8048999905586243}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":false},"content_urls":{"pdf":"https://content.openalex.org/works/W2000246970.pdf"},"referenced_works_count":31,"referenced_works":["https://openalex.org/W19835385","https://openalex.org/W1965292177","https://openalex.org/W1971242419","https://openalex.org/W1977149004","https://openalex.org/W1991540733","https://openalex.org/W1991644988","https://openalex.org/W1998522293","https://openalex.org/W2010801138","https://openalex.org/W2020022643","https://openalex.org/W2028445147","https://openalex.org/W2030827382","https://openalex.org/W2038414910","https://openalex.org/W2038916577","https://openalex.org/W2045725488","https://openalex.org/W2051071528","https://openalex.org/W2051218908","https://openalex.org/W2060003702","https://openalex.org/W2062212257","https://openalex.org/W2067467942","https://openalex.org/W2107457439","https://openalex.org/W2117706207","https://openalex.org/W2136556394","https://openalex.org/W2137663279","https://openalex.org/W2147150779","https://openalex.org/W2152911432","https://openalex.org/W2154543415","https://openalex.org/W2170734795","https://openalex.org/W2300039368","https://openalex.org/W2317200830","https://openalex.org/W2399372272","https://openalex.org/W4247653438"],"related_works":["https://openalex.org/W2235519817","https://openalex.org/W2154543415","https://openalex.org/W7169844535","https://openalex.org/W2158078460","https://openalex.org/W26760683","https://openalex.org/W2106892694","https://openalex.org/W2117706207","https://openalex.org/W2047450350","https://openalex.org/W7220775917"],"abstract_inverted_index":{"While":[0,86],"myriad":[1],"molecular":[2,220],"formats":[3],"for":[4,40,61,110,134,175,247],"bispecific":[5,28,55,244],"antibodies":[6],"have":[7,31],"been":[8,32],"examined":[9],"to":[10,36,51,80],"date,":[11],"the":[12,19,81,89,103,237],"simplest":[13],"structures":[14],"are":[15],"often":[16],"based":[17],"on":[18,67],"scFv.":[20],"Issues":[21],"with":[22,71,167],"stability":[23,169],"and":[24,100,113,132,140,160,171,178,198,230],"manufacturability":[25],"in":[26,125,137,149,190,209],"scFv-based":[27,243],"molecules,":[29],"however,":[30],"a":[33,53,72,95,210,240],"significant":[34],"hindrance":[35],"their":[37,199],"development,":[38],"particularly":[39],"high-concentration,":[41],"stable":[42],"formulations":[43],"that":[44,155],"allow":[45],"subcutaneous":[46,248],"delivery.":[47],"Our":[48,203],"aim":[49],"was":[50,98],"generate":[52],"tetravalent":[54],"molecule":[56],"targeting":[57],"two":[58],"inflammatory":[59],"mediators":[60],"synergistic":[62],"immune":[63],"modulation.":[64],"We":[65],"focused":[66],"an":[68,77,84,150],"scFv-Fc-scFv":[69],"format,":[70],"flexible":[73],"(A4T)3":[74],"linker":[75],"coupling":[76],"additional":[78],"scFv":[79,106],"C-terminus":[82],"of":[83,88,127,239],"scFv-Fc.":[85],"one":[87],"lead":[90],"scFvs":[91,193],"isolated":[92],"directly":[93],"from":[94],"na\u00efve":[96],"library":[97],"well-behaved":[99],"sufficiently":[101],"potent,":[102],"parental":[104],"anti-CXCL13":[105],"3B4":[107,144],"required":[108],"optimization":[109],"affinity,":[111],"stability,":[112],"cynomolgus":[114,179],"ortholog":[115],"cross-reactivity.":[116],"To":[117],"achieve":[118],"this,":[119],"we":[120],"eschewed":[121],"framework-based":[122],"stabilizing":[123],"mutations":[124,189],"favor":[126],"complementarity-determining":[128],"region":[129],"(CDR)":[130],"mutagenesis":[131],"re-selection":[133],"simultaneous":[135],"improvements":[136],"both":[138,176],"affinity":[139,174],"thermal":[141,157],"stability.":[142],"Phage-displayed":[143],"CDR-mutant":[145],"libraries":[146],"were":[147,183,194],"used":[148],"aggressive":[151],"\"hammer-hug\"":[152],"selection":[153],"strategy":[154],"incorporated":[156],"challenge,":[158],"functional,":[159],"biophysical":[161,200],"screening.":[162],"This":[163,233],"approach":[164],"identified":[165],"leads":[166],"improved":[168],"and>18-fold,":[170],"4,100-fold":[172],"higher":[173],"human":[177],"CXCL13,":[180],"respectively.":[181],"Improvements":[182],"exclusively":[184],"mediated":[185],"through":[186],"only":[187],"4":[188,228],"VL-CDR3.":[191],"Lead":[192],"reformatted":[195],"into":[196],"scFv-Fc-scFvs":[197],"properties":[201],"ranked.":[202],"final":[204],"candidate":[205],"could":[206],"be":[207],"formulated":[208],"standard":[211],"biopharmaceutical":[212],"platform":[213],"buffer":[214],"at":[215,227],"100":[216],"mg/ml":[217],"with<2%":[218],"high":[219],"weight":[221],"species":[222],"present":[223],"after":[224],"7":[225],"weeks":[226],"\u00b0C":[229],"viscosity<15":[231],"cP.":[232],"workflow":[234],"has":[235],"facilitated":[236],"identification":[238],"truly":[241],"manufacturable":[242],"therapeutic":[245],"suitable":[246],"administration.":[249]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":3}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}